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Edited by Robert B. RussellAbstract Transcriptional regulation depends on sequence-
speciﬁc binding of regulatory proteins to their responsive ele-
ments in viral DNA. The papillomavirus E2 protein binds to
DNA through the consensus sequence ACCG-NNNN-CGGT,
activating or inhibiting viral replication. Through molecular
dynamics simulations we were able to characterize the role of
the DNA molecule on E2 binding region (named a1E2) confor-
mation, acquiring structural insights for previous works suggest-
ing an unfolded to folded transition upon a1E2 complexation to
DNA. Moreover, the results indicate sites to guide the design
of a1E2 synthetic derivatives to inhibit the HPV infection.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The E2 protein is the major regulatory protein from papillo-
mavirus. It acts as both recognition and regulator factors of
the early transcription in infected cells [1,2]. The E2 protein
is composed by an N-terminal trans-activation domain and a
C-terminal DNA binding domain (DBD), separated by a very
ﬂexible proline rich linker [2]. While the N-terminal domain is
responsible for the interaction with viral protein E1 and other
cellular factors like Sp1, TFIIB, and AMF-1 [3–5], the C-ter-
minal domain (E2CT) is responsible for homo- and hetero-
dimerization and DNA binding. The E2CT recognizes and
speciﬁcally binds to double-stranded DNA comprising the pal-
indromic consensus sequence 5 0ACCG-NNNN-CGGT3 0,
where N can be any nucleotide. The three-dimensional struc-
ture of the E2CT has been determined by both X-ray [6–13]
and NMR method [14–16] for several viral strains. These
structures revealed the E2CT as a dimeric b-barrel composed
of four anti-parallel b-sheets with two a-helices (a-helix-1
and a-helix-2) aligned perpendicular to the b-barrel [2]. Most
of the amino acids involved in DNA binding are located in*Corresponding author. Address: Centro de Biotecnologia, Univer-
sidade Federal do Rio Grande do Sul, Av Bento Gonc¸alves 9500, CP
15005, Porto Alegre 91500-970, RS, Brazil. Fax: +55 51 3316 7309.
E-mail address: hverli@cbiot.ufrgs.br (H. Verli).
0014-5793/$34.00  2008 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2008.09.041a-helix-1, which is described as the recognition helix [1,2],
whereas recent data indicate that such protein–DNA recogni-
tion is additionally tuned by mechanical and dynamical prop-
erties of the whole protein scaﬀold [17]. The a-helix-1,
comprised between residues Arg296 and Arg307 for HPV-18
E2 protein [6], added by residues in b2–b3 loop [17], partici-
pate in a hydrogen bond network with the DNA binding site,
allowing the occurrence of sequence-speciﬁc contacts with the
DNA major groove.
Recent data also demonstrate that a synthetic peptide de-
rived from HPV-16 recognition helix (named a1E2), fully capa-
ble of ACCG recognition, is indeed capable to bind and
speciﬁcally recognize DNA sequences, even outside the context
of the full protein [18]. The authors pointed that this peptide is
intrinsically unfolded in solution, acquiring some degree of
secondary structure only upon complex formation [18], sug-
gesting that binding is independent of a pre-existent helical
conformation and leads to a folding transition.
This recognition helix was previously observed by NMR, in
the absence of its DBD, to present fast amide exchange rates,
suggesting this helix as a particularly ﬂexible region of E2 pro-
tein [14], a phenomenon already identiﬁed for a number of
other DNA binding proteins, as for GCN4 [19], trp repressor
[20] and ets of Fli-1 [21], so probably constituting a common
theme in protein–DNA recognition. It was latter demon-
strated, both by NMR [22] and molecular dynamics (MD) sim-
ulation [23], that this same helix display limited ﬂexibility when
bounded to DNA. However, while such unfolded to folded
transition was already demonstrated to occur in other
biological systems [24], the structural evidence supporting such
phenomenon on a1E2 is still absent.
Recent works had described the recognition between E2
proteins and its binding to DNA, as for HPV-16 and BPV-1
[17,23,25], pointing to a dynamic picture of DBD-E2 recogni-
tion where both DNA conformational changes and protein
intrinsic deformability appears to cooperate in the recognition
process. Nevertheless, such behavior do not explain the
unfolded to folded transition of a1E2 upon binding to DBD
[18], a process suggesting an induction of conformational
changes in E2 by DNA, i.e. a mutual induced ﬁt process. In
this context the current work intends to evaluate the dynamical
aspects of the mutual recognition between a1E2 and its speciﬁc
DNA binding site through MD of both unbounded and
bounded forms of these two molecules. The obtained results al-
lowed the explaining of an apparent contradiction between theblished by Elsevier B.V. All rights reserved.
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absence of secondary structure on a1E2 in solution and its
folded state when bounded to the DBD. Additionally, it sug-
gest potential targets, i.e. nucleotides, and references, i.e. ami-
no acids, for the development of synthetic compounds able to
inhibit the E2 protein binding to DNA.2. Methods
2.1. Nomenclature and software
The recommendations and symbols of nomenclature as proposed by
IUPAC [26] were used. The manipulation of structures was performed
with VMD [27] and PyMol [28], while the homology modeling was per-
formed with the Swiss-PDB Viewer [29]. All the MD calculations and
analysis were performed using the GROMACS package [30] and AM-
BER99 force ﬁeld [31]. Analyses of DNA structural parameters were
carried out using CURVES [32,33], while PROCHECK [34] was
employed to evaluate the content of peptide secondary structure.
2.2. Structure reﬁnement and molecular simulations
The structure of the E2 protein complexed to DNA was retrieved
from Protein Data Bank under code 1JJ4 [6]. Based on this structure,
four diﬀerent systems were simulated for 30.0 ns: (1) the isolated DNA
sequence containing E2 DBD; (2) the isolated a-helix 1, from E2 pro-
tein (a1E2 peptide, residues 294-311); (3) the complex formed by DNA
and a1E2 peptide and; (4) the complex formed by a mutated DNA se-Fig. 1. MD analyses as a function of time or residue number for a1E2 in its
296–303 (green), when complexed with the non-mutated DBD (red) and wi
RMSD from crystal structure; (B) all-atom average root mean square ﬂuctua
C-terminal residues; (D) a-helix length; (E) average pseudo dihedral n (i.e. th
and Cai+3) [47] over the peptide chain, and F) ellipticity at 222 nm (percentquence and a1E2 peptide. These structures were solvated in a rectangu-
lar box using TIP3 P water model [35] by a layer of at least 10 A˚ from
the solute (a1E2, DNA or a1E2-DNA complex) atoms. Counter ions
(Na+ or Cl) were added to neutralize the systems charges. The MD
protocol employed was based on previous MD studies [36]. The Lincs
and Settle methods [37,38] were applied to constrain covalent bond
lengths, allowing an integration step of 2 fs after an initial energy
minimization using steepest descents algorithm under periodic
boundary conditions. The so obtained systems, composed by a1E2–
solvent–ions, DNA–solvent–ions, and a1E2–DNA–solvent–ions (in
its G22C21C20A19 or A22A21A20A19 containing sequences) were heated
slowly from 50 K to 310 K, in steps of 5 ps, in which the reference tem-
perature was increased by 50 K. Temperature and pressure were kept
constant during all simulations by coupling the protein, nucleic acid,
ions, and solvent to external temperature and pressure baths with cou-
pling constants of s = 0.1 and 0.5 ps [39], respectively. No restraints
were applied after the thermalization phase. The electrostatic interac-
tions were evaluated by the particle–mesh Ewald method [40] with a
charge grid spacing of 1.2 A˚, while Coulomb and Lennard–Jones
interactions were evaluated using a 9.0 A˚ atom-based cutoﬀ [41]. The
analyses were performed in all trajectory length.
The amino acids of a1E2 peptide were numbered following the
crystallographic sequence (from N- to C-terminal)
Gly294-Asp295-Arg296-Asn297-Ser298-Leu299-Lys300-Cys301-
Leu302-Arg303-Tyr304-Arg305-Leu306-Arg307-Lys308-His309-
Ser310-Asp311, and the numbering of the simulated native DNA
sequence is
5 0-C1 A2 A3 C4 C5 G6 A7 A8 T9 T10C11G12G13T14T15G16-3 0
3 0-G32T31T30G29G28C27T26T25A24A23G22C21C20A19A18C17-5 0,uncomplexed form for all amino acid residues (black) and for residues
th the mutated DBD (blue) for the following properties: (A) all-atom
tion (RMSF) over the 30.0 ns simulations; (C) distance between N- and
e dihedral formed by 4 consecutive a-carbon atoms Cai, Cai+1, Cai+2,
age of time in which the residues presents a helix character) [48].
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condition 4 is
5 0-C1 A2 A3 C4 C5 G6 A7 A8 T9 T10T11T12T13T14T15G16-3 0
3 0-G32T31T30G29G28C27T26T25A24A23A22A21A20A19A18C17-5 03. Results and discussion
3.1. Simulation stability
As a ﬁrst assessment to the overall progress of the performed
simulations, the root mean square deviation (RMSD) of each
system was evaluated from the crystallographic structure as a
function of time. Such deviation has shown to be highly depen-
dent on the presence of DNA, as well as the correct DBD com-
plexation. The unbounded a1E2 peptide presents an average
RSMD of about 0.6 nm, the a1E2 complexed to mutate
DBD presents a RMSD about 0.45 nm, and the a1E2:DNA
(native) presents an average RMSD of 0.3 nm (Fig. 1A). Addi-
tionally, in the complexed peptide a subset of residues (296–
303) interacts more strongly with the native DBD, exhibiting
a RMSD lower than 0.2 nm (Fig. 1A). This increase in peptide
deviation from crystallographic structure in the absence of cor-
rect DBD indicates a lost of a-helical content, a pattern also
suggested by the distance between C- and N-terminal residues
(Fig. 1C). In this case, the DNA bounded to a1E2 shows aFig. 2. Conformational modiﬁcation in the a1E2 peptide, show as ribbons,
native DBD sequence (B), and to mutated DBD (C). The DNA molecules are
content of the a1E2 peptide was predicted by PROCHECK in its crystallogra
MD simulations. Accordingly, the native (B) and the mutated DBD (C) seqdistance almost 1.5 nm larger than the uncomplexed peptide
(Fig. 1C). Thus, such reduction in distance between C- and
N-terminal residues is possibly achieved through modiﬁcation
in the peptide secondary structure by the unfolding of the a-he-
lix and approximation of the termini (see further).
3.2. Structural ﬂuctuation of peptide
In order to assess the relative mobility of diﬀerent regions of
the peptide we analyzed the root mean square ﬂuctuations
(RMSF) as a function of residue number for both free and
DBD complexed peptides (Fig. 1B). Globally, the RMSF of
the free peptide and the peptide complexed to mutate DBD
are higher than a1E2 in complex with native DBD, mainly in
its N-terminal. In C-terminal the similar behaviors in situa-
tions can be related to a region of a1E2 peptide already ﬂexible
in its complexed form, not participating in major interactions
with DBD.
3.3. Peptide secondary structure and DNA analysis
In order to characterize the extent of decrease in secondary
structure content, we analyzed the a-helix length, the average
pseudo dihedral n (i.e. the dihedral formed by 4 consecutive
a-carbon atoms Cai, Cai+1, Cai+2, and Cai+3) [42], and the
ellipticity at 222 nm (percentage of time in which the residuesafter 30.0 ns MD simulations when uncomplexed (A), complexed to
presented as contour surfaces. In each system, the secondary structure
phic form and in its ﬁnal conformation, as described by the performed
uences are also presented.
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peptide over the simulation (Fig. 1D–F). From these data, a
progressive decrease in secondary structure elements for the
free peptide may be observed through the simulation trajec-
tory, while no signiﬁcant change is observed for the complex.
On the other hand, the mutation in DBD apparently promotes
a lowering in a1E2 secondary structure stability: the pseudo
dihedral n indicates a lost on a-helical content (reference value
around 45) upon DBD removal or mutation (Fig. 1E), a
behavior accompanied by a strong decrease in ellipticity
(Fig. 1F) and by the average phi and psi angles for the peptide,
of 79.6 ± 5 and 16.8 ± 5.0 for its unbounded form,
71.4 ± 3 and 34.8 ± 3.9 when complexed to DBD and
76.9 ± 7.2 and 24.9 ± 5.4 when bounded to the mutated
DBD, compared to the reference values of 65.3 ± 11.9 and
39.4 ± 11.3, respectively for phi and psi angles [44]. The ex-
tent of changes in secondary structure was further evaluated by
PROCHECK (Fig. 2), conﬁrming the stability of the second-
ary structure content in the presence of correct DBD, so point-
ing to the role of DNA to preservation of the a-helix
conformation in a1E2. On the other hand, the unbounded pep-
tide loses almost half of its content in secondary structure
when free in solution, while maintaining an a-helix conforma-
tion between residues 296–303 (Fig. 2A). This subset of resi-
dues appears to characterize a foldamer, i.e. a region that
would be responsible to initiate and support the folding of
the remaining residues when complexed to DBD.Fig. 3. Conformational proﬁle of the DNA molecule after 30.0 ns MD simul
(red), and in its crystallographic conformation (back), as described under PD
are presented as average and standard deviation values: twist (), roll (), XThe description of DNA properties is a diﬃcult task, since it
presents a high mobility [45–47], despite of the apparent lim-
ited conformational distribution as suggested by the plethora
of crystallographic data. For DNA, a ﬁnite though large series
of parameters can be evaluated, such as rotations, translations
and displacements between the bases [48]. No signiﬁcant mod-
iﬁcations in DNA conformation were observed between com-
plexed and free strands (Fig. 3), within standard deviation
values, indicating that a1E2 have little inﬂuence on DNA base
displacements and curvature features.
3.4. Forces participating in DBD – a1E2 recognition
The capability to describe the ﬂexible nature of a molecular
system, as well as its dependence on the solution composition
may be considered as one of the main advantages associated
with MD. During this dynamic process, the quantiﬁcation
and contribution of speciﬁc forces for the process under eval-
uation may also be assessed, as the interaction energy between
a ligand and the amino acid residues from a speciﬁc binding
protein, as well as with the DNA. In fact, this approach allows
the description, in a high level of accuracy, of experimental de-
rived properties as aﬃnity diﬀerences originated from muta-
genesis data [49]. In this sense, aiming to obtain the speciﬁc
contribution of each amino acid residue to the complex forma-
tion with DBD, as well as of each DNA basis, the main inter-
molecular interactions participating in the a1E2:DNA were
evaluated (Tables 1 and 2).ations in its uncomplexed form (green), complexed to the a1E2 peptide
B code 1JJ4. The following structural properties of the DNA molecule
-disp (A˚), and slide (A˚).
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acting with E2 DBD it may be deduced which residues would
present a major role on complexation. As a consequence, such
contribution is expected to support the ligand-based design of
new synthetic derivatives of a1E2. From the data presented in
Table 1, it can be observed that amino acid residues most
important for binding and complex formation with DBD are
located in the 296–303 region. Such data agrees with the pos-
sible role of this region as a foldamer in this system, i.e. the
nucleation point for folding of this a-helix structure upon
binding to DNA. Additionally, the role of basic amino acid
residues became obvious, with the non-polar or acidic residues
acting probably as spacers for an ideal orientation of Arg, Asn
and Lys residues. On the other hand, upon mutation in DBD
its interaction with a1E2 signiﬁcantly decreases in comparison
to the native DBD (data no shown).
While the identiﬁcation of the main amino acid residues to
DBD complexation may contributes in ligand-based drug de-
sign, the elucidation of the main DNA bases for such process
may serve as a guide to structural-based design of new deriva-
tives. As shown in Table 2, the analysis of the speciﬁc contri-Table 1
Average interaction energies between a1E2 amino acid residues and
DBD
a1E2 amino acid residues (kJ/mol)
a
Gly294 50.4 ± 21.3
Asp295 1.2 ± 2.05
Arg296 81.5 ± 31.6
Asn297 64.1 ± 17.2
Ser298 24.8 ± 22.5
Leu299 0.0 ± 0.2
Lys300 56.0 ± 19.5
Cys301 6.7 ± 2.8
Leu302 0.0 ± 0.2
Arg303 87.5 ± 55.7
Tyr304 6.3 ± 4.2
Arg305 10.6 ± 14.5
Leu306 0.0 ± 0.0
Arg307 73.1 ± 22.5
Lys308 40.6 ± 30.6
His309 0.2 ± 1.9
Ser310 0.0 ± 0.0
Asp311 0.0 ± 0.4
aAverage values from the sum of Coulomb and Lennard–Jones com-
ponents over the 30.0 ns of simulation.
Table 2
Average interaction energies between DBD bases and a1E2 peptide
Bases from the DBS (kJ/mol)a
T10 50.3 ± 28.6
C11 65.9 ± 49.9
G12 131.6 ± 51.2
G13 87.4 ± 35.0
T14 1.9 ± 3.6
T15 0.3 ± 1.3
A18 52.4 ± 26.1
A19 86.4 ± 28.7
C20 15.2 ± 11.1
C21 7.5 ± 5.5
G22 0.5 ± 1.3
A23 0.0 ± 0.0
aAverage values from the sum of Coulomb and Lennard–Jones com-
ponents over the 30.0 ns of simulation.bution of DBD bases to the interaction with a1E2 peptide
allows the observer to note that the two DNA strands do
not contributes equally to the binding process. Additionally,
the participation of residues outside the speciﬁc recognition se-
quence appears to be important to the complexation process,
as A18 and A19.4. Conclusion
Here, we presented a conformational study of protein E2
recognition helix from papillomavirus type 18 (HPV-18)
bounded and unbounded to its DBD through MD simulations.
The data shows that the a1E2 peptide lost most of its second-
ary structure around its C-terminal region, conﬁrming experi-
mental data indicating that it is predominantly unfolded when
free in solution. Accordingly, the results demonstrate that the
peptide binding to its speciﬁc site at DNA is not dependent on
a conformational state previously existent in solution, but in-
duced upon complexation. In addition, the data also indicates
that the peptide have no major inﬂuence on inherent DNA
ﬂexibility. Altogether, the data allowed the postulation of a
possible mechanism where residues 296–303 would constitute
a foldamer, capable to support and initiate the peptide folding
after DBD complexation.
Globally, our results are in close agreement with previous
studies [18], explaining at the atomic level the forces responsi-
ble for the intrinsically unfolded conditions of a1E2 in solu-
tion, as well as its folding after complex formation. These
results characterize a mutual induced ﬁt process and support
the unfolding to folding transition in a1E2. Additionally,
through characterization of speciﬁc contributions of both
a1E2 amino acid residues, as well as DBD bases, in the absence
of the whole protein context, the obtained results may contrib-
ute in the design of new low molecular weight synthetic a1E2
analogues, capable to compete for its DNA binding site and
so hindering the advance of HPV infection.
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